3,3-pentamethylene-1,2,3,9-tetrahydro-imidazo[5,1-b]quinazoline-1,9-dione | 874583-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3,3-pentamethylene-1,2,3,9-tetrahydro-imidazo[5,1-b]quinazoline-1,9-dione
• 英文别名: spiro[2H-imidazo[5,1-b]quinazoline-3,1'-cyclohexane]-1,9-dione
• CAS: 874583-62-7
• 化学式: C₁₅H₁₅N₃O₂
• 分子量: 269.303
• InChiKey: JCWCDYKAIPYPSW-UHFFFAOYSA-N

物化性质

• 熔点：
  350 °C(Solv: dimethyl sulfoxide (67-68-5); ethanol (64-17-5))
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.13
• 重原子数：
  20.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  63.99
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  3,3-pentamethylene-1,2,3,9-tetrahydro-imidazo[5,1-b]quinazoline-1,9-dione 、 1-(氯乙酰基)-4-(2-甲氧基苯基)哌嗪盐酸盐 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以78%的产率得到
  参考文献：
  名称：

  Ligand design and synthesis of new imidazo[5,1-b]quinazoline derivatives as α1-adrenoceptor agonists and antagonists

  摘要：

  A series of new imidazo[5,1-b]quinazoline derivatives (VII-IX) was designed, synthesized, and biologically evaluated for their in vivo hypotensive or hypertensive activities. The design of these compounds was based upon the molecular modeling Simulation of the fitting values and conformational energy values of the best-fitted conformers to both the alpha(1)-adrenoceptor (alpha(1)-AR) agonist and alpha(1)-adrenoceptor (alpha(1)-AR) antagonist hypotheses. These hypotheses were generated from their corresponding lead compounds using CATALYST software. The simulation Studies predicted that compounds IXa and IXc Would have probable affinity for the alpha(1)-AR antagonist hypothesis, while compounds IXb, IXc, and IXg predicted a higher affinity for the alpha(1)-AR agonist hypothesis. In vivo biological evaluation of these compounds for their effects on the blood pressure of normotensive cats was consistent with the results of molecular modeling studies, where compounds IXa and IXe exhibited hypotensive activity, while compounds IXb, IXc, and IXg resulted in increasing the blood pressure of the experimental animals at different doses. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.037
• 作为产物：
  描述：

  4-methylthio-1,3-diazaspiro[4,5]dec-3-en-2-one 、 邻氨基苯甲酸 反应 3.0h， 以44.5%的产率得到3,3-pentamethylene-1,2,3,9-tetrahydro-imidazo[5,1-b]quinazoline-1,9-dione
  参考文献：
  名称：

  Ligand design and synthesis of new imidazo[5,1-b]quinazoline derivatives as α1-adrenoceptor agonists and antagonists

  摘要：

  A series of new imidazo[5,1-b]quinazoline derivatives (VII-IX) was designed, synthesized, and biologically evaluated for their in vivo hypotensive or hypertensive activities. The design of these compounds was based upon the molecular modeling Simulation of the fitting values and conformational energy values of the best-fitted conformers to both the alpha(1)-adrenoceptor (alpha(1)-AR) agonist and alpha(1)-adrenoceptor (alpha(1)-AR) antagonist hypotheses. These hypotheses were generated from their corresponding lead compounds using CATALYST software. The simulation Studies predicted that compounds IXa and IXc Would have probable affinity for the alpha(1)-AR antagonist hypothesis, while compounds IXb, IXc, and IXg predicted a higher affinity for the alpha(1)-AR agonist hypothesis. In vivo biological evaluation of these compounds for their effects on the blood pressure of normotensive cats was consistent with the results of molecular modeling studies, where compounds IXa and IXe exhibited hypotensive activity, while compounds IXb, IXc, and IXg resulted in increasing the blood pressure of the experimental animals at different doses. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.037